Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 2-(3-{1-Carboxy-5-[(6-18F-Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (Pyl) in Patients With High Risk and Biochemically Recurrent Prostate Cancer No ClinicalTrials.gov identifier reported
- 233975_235097_VWF.ag_PR_RI_MC_Mich. CA2 Professional = Jeryl Bischoff No ClinicalTrials.gov identifier reported
- 233C Clinical Evaluation of the Xpert Xpress MVP Test No ClinicalTrials.gov identifier reported
- 23787 No ClinicalTrials.gov identifier reported
- 23G-BARDA - ONSD for Head Trau No ClinicalTrials.gov identifier reported
- 23G-BARDA - Whole Program - Ra No ClinicalTrials.gov identifier reported
- 23G-NIH--Ultra-efficient, high No ClinicalTrials.gov identifier reported
- 23Hc011 No ClinicalTrials.gov identifier reported
- 23Sust090 No ClinicalTrials.gov identifier reported
- 24001, ABL90 FLEX PLUS Ki Method Comparison study in whole blood samples. NCT06724081
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported
- 24023 – ZEUS (510K) Method Comparison Adult: Arterial and Venous blood for PICO A and safePICO A No ClinicalTrials.gov identifier reported